Did FDA remove the menopause hormone therapy boxed warning? What changed in 2026
FDA approved specified boxed-warning changes for an initial group of menopausal hormone therapy products in February 2026. It did not erase every warning from every product, approve compounded hormones, or make all routes and formulations interchangeable. Read the current product-specific label.
FDA did not remove every warning from every menopausal hormone therapy product. On February 12, 2026, FDA announced approved labeling changes for an initial six products that removed specified cardiovascular-disease, breast-cancer, and probable-dementia statements from their boxed warnings. Product-specific contraindications and risk information remain, and FDA did not seek removal of the endometrial-cancer boxed warning for systemic estrogen-alone products.12
The accurate takeaway is “read the current label for the exact product,” not “hormone therapy has no boxed warning” and not “old warnings still apply unchanged to every route.”
A request, an approved supplement, and a class claim are different
FDA first requested labeling changes across relevant approved products. Each application holder then had to submit labeling changes, and FDA had to approve product-specific supplements. The February announcement named six initial approved changes.1
| Record | What it establishes | What it does not establish |
|---|---|---|
| FDA labeling request | The agency asked application holders to submit specified changes | That every label changed that day |
| Approved labeling supplement | FDA approved revised labeling for that product and application | A class-wide change for every product |
| Current prescribing information | The warnings, contraindications, indications, route, dose, and population for the exact product | That a different formulation shares the same label |
| Compounded prescription | A prescriber and pharmacy made a patient-specific preparation | FDA-approved labeling or premarket review |
| Clinic summary | The clinic's interpretation | The current official product record |
This sequence matters because a screenshot of FDA’s request can be accurate but incomplete for a product whose label has not yet been updated.
The removed statements were not the only risk information
FDA’s action focused on specific boxed-warning language related to cardiovascular disease, breast cancer, and probable dementia.12 It did not declare those outcomes impossible, erase contraindications, or remove all warnings and precautions from prescribing information.
FDA also did not seek removal of the boxed warning about endometrial cancer from systemic estrogen-alone products.2 The presence or absence of a uterus, use of a progestogen, route, dose, timing, and product are distinct clinical variables. A high-level news headline cannot resolve them.
Local vaginal estrogen products and systemic products also perform different jobs and have different exposure and labeling contexts. “Estrogen” is not one interchangeable product category.
Compounded and pellet products cannot borrow the change
An FDA-approved label change attaches to the named approved product. It does not approve a compounded cream, troche, injection, or pellet, even if it contains a similar hormone. Compounded drugs do not carry FDA-approved prescribing information and are not reviewed before marketing for safety, effectiveness, or quality in the same way.
The compounded-hormone guide explains that “bioidentical” describes chemistry, not approval. The pellets-versus-patches, gels, and injections guide owns the route and reversibility comparison.
If a clinic says “FDA removed the black box, so our pellet is now proven safe,” ask for the exact approved application and label. The claim crosses from a product-specific labeling action to an unreviewed formulation.
Timing language needs careful translation
FDA’s communications discuss benefit-risk considerations related to age and time since menopause onset.23 That is not a universal start-by date, guaranteed low-risk window, or dosing recommendation. Product labels and professional guidance still require individualized assessment.
A useful consultation record separates:
- the symptom or indication being addressed;
- age and menopause timeline;
- uterus status and relevant history;
- exact hormone, route, strength, and schedule;
- current label and contraindications;
- alternatives and nonhormonal options; and
- who owns follow-up and product changes.
This article provides a label-reading framework, not a personal hormone-therapy decision.
How to verify whether a label changed
- Name the exact finished product. Record brand or generic manufacturer, active ingredient, route, strength, dosage form, and application number if available.
- Open the current official prescribing information. Do not rely on a news headline, clinic handout, or old package insert.
- Read beyond the box. Review indication, contraindications, warnings, precautions, dosing, and patient information as one record.
- Keep routes and formulations separate. Do not transfer systemic, local, oral, transdermal, or compounded claims without product-specific support.
- Date the decision. Labeling is changing product by product; preserve review date and recheck before refills or a switch.
The decisive question is not “Did FDA admit hormone therapy is safe?” It is “What does the current FDA-approved label for this exact product say now, which risk statements remain, and does the clinic’s claim stay inside that record?”
Sources
- U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026 announcement identifying the initial six product approvals and the specified boxed-warning changes. Accessed .
- U.S. Food and Drug Administration. FDA Requests Labeling Changes to Clarify Benefit-Risk Considerations for Menopausal Hormone Therapies. Agency request, scope, distinctions among systemic and local products, and warning language FDA did and did not seek to remove. Accessed .
- U.S. Food and Drug Administration. FDA Grand Rounds: Menopausal Hormone Therapy Labeling. FDA scientific context for the labeling review and benefit-risk communication changes. Accessed .